Formycon AG (CHIX:FYBD) Total Equity: €399.14 Mil (As of Dec. 2025)


CHIX:FYBD Formycon AG CHIX:FYBD
56 GF Score
Price €63.30
GF Value €120.94
! 5 Warning Signs
View Full Analysis

What is Formycon AG Total Equity?

Formycon AG CHIX:FYBD 56 Total Equity is €399.14 Mil as of Dec. 2025. GuruFocus rates CHIX:FYBD with a GF Score™ of 56/100 and a GF Value™ of €120.94. The stock has 5 warning signs investors should review.

Formycon AG's total equity for the quarter that ended in Dec. 2025 was €399.14 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Formycon AG Total Equity Historical Data

* Premium members only.

The historical data trend for Formycon AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formycon AG Total Equity Chart

Formycon AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.89 356.58 502.75 461.84 399.14

Formycon AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 502.75 576.30 461.84 408.33 399.14
CHIX:FYBD
56GF Score
Formycon AG CHIX:FYBD
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formycon AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Formycon AG's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=739.527-340.391
=399.14

Formycon AG's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=739.527-340.391
=399.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €399.14 Mil mean?
Formycon AG (CHIX:FYBD) has a Total Equity of €399.14 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Formycon AG and its competitors.
Is Formycon AG's Total Equity too high?
Formycon AG's current Total Equity is €399.14 Mil. Overall, Formycon AG has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's Total Equity compare to VRTX and REGN?
Formycon AG's Total Equity of €399.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Formycon AG and its competitors. Formycon AG's current Total Equity is €399.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Formycon AG (CHIX:FYBD) has a current Total Equity of €399.14 Mil. The stock's GF Value™ is €120.94, compared to a current price of €63.30 — trading 47.7% below its estimated fair value. The current Total Equity is €399.14 Mil. Formycon AG's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Formycon AG (CHIX:FYBD), the current Total Equity is €399.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formycon AG (CHIX:FYBD) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €63.30 is trading 47.7% below its estimated GF Value™ of €120.94.

Key valuation signals for CHIX:FYBD:

  • Total Equity: €399.14 Mil
  • GF Value™: €120.94 vs. price of €63.30 (47.7% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the CHIX:FYBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
56GF Score

Get the complete analysis for CHIX:FYBD

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.30
Price
€120.94
GF Value